193 related articles for article (PubMed ID: 25344862)
1. A novel calcium-dependent mechanism of acquired resistance to IGF-1 receptor inhibition in prostate cancer cells.
Fahrenholtz CD; Greene AM; Beltran PJ; Burnstein KL
Oncotarget; 2014 Oct; 5(19):9007-21. PubMed ID: 25344862
[TBL] [Abstract][Full Text] [Related]
2. Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts.
Fahrenholtz CD; Beltran PJ; Burnstein KL
Mol Cancer Ther; 2013 Apr; 12(4):394-404. PubMed ID: 23348048
[TBL] [Abstract][Full Text] [Related]
3. Effect of a low-fat diet combined with IGF-1 receptor blockade on 22Rv1 prostate cancer xenografts.
Konijeti R; Koyama S; Gray A; Barnard RJ; Said JW; Castor B; Elashoff D; Wan J; Beltran PJ; Calzone FJ; Cohen P; Galet C; Aronson WJ
Mol Cancer Ther; 2012 Jul; 11(7):1539-46. PubMed ID: 22562985
[TBL] [Abstract][Full Text] [Related]
4. Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.
Becker MA; Hou X; Tienchaianada P; Haines BB; Harrington SC; Weroha SJ; Sathyanarayanan S; Haluska P
BMC Cancer; 2016 Oct; 16(1):814. PubMed ID: 27765027
[TBL] [Abstract][Full Text] [Related]
5. Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody.
Shin DH; Min HY; El-Naggar AK; Lippman SM; Glisson B; Lee HY
Mol Cancer Ther; 2011 Dec; 10(12):2437-48. PubMed ID: 21980128
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
7. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.
Dayyani F; Parikh NU; Varkaris AS; Song JH; Moorthy S; Chatterji T; Maity SN; Wolfe AR; Carboni JM; Gottardis MM; Logothetis CJ; Gallick GE
PLoS One; 2012; 7(12):e51189. PubMed ID: 23300537
[TBL] [Abstract][Full Text] [Related]
8. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
[TBL] [Abstract][Full Text] [Related]
9. Effects of calorie restriction and IGF-1 receptor blockade on the progression of 22Rv1 prostate cancer xenografts.
Galet C; Gray A; Said JW; Castor B; Wan J; Beltran PJ; Calzone FJ; Elashoff D; Cohen P; Aronson WJ
Int J Mol Sci; 2013 Jul; 14(7):13782-95. PubMed ID: 23823800
[TBL] [Abstract][Full Text] [Related]
10. Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy.
Beltran PJ; Calzone FJ; Mitchell P; Chung YA; Cajulis E; Moody G; Belmontes B; Li CM; Vonderfecht S; Velculescu VE; Yang G; Qi J; Slamon DJ; Konecny GE
Clin Cancer Res; 2014 Jun; 20(11):2947-58. PubMed ID: 24727326
[TBL] [Abstract][Full Text] [Related]
11. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis.
Huang HJ; Angelo LS; Rodon J; Sun M; Kuenkele KP; Parsons HA; Trent JC; Kurzrock R
PLoS One; 2011; 6(10):e26060. PubMed ID: 22022506
[TBL] [Abstract][Full Text] [Related]
12. Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models.
Weyer-Czernilofsky U; Hofmann MH; Friedbichler K; Baumgartinger R; Adam PJ; Solca F; Kraut N; Nguyen HM; Corey E; Liu G; Sprenger CC; Plymate SR; Bogenrieder T
Mol Cancer Ther; 2020 Apr; 19(4):1059-1069. PubMed ID: 32054790
[TBL] [Abstract][Full Text] [Related]
13. ERK phosphorylation is predictive of resistance to IGF-1R inhibition in small cell lung cancer.
Zinn RL; Gardner EE; Marchionni L; Murphy SC; Dobromilskaya I; Hann CL; Rudin CM
Mol Cancer Ther; 2013 Jun; 12(6):1131-9. PubMed ID: 23515613
[TBL] [Abstract][Full Text] [Related]
14. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors.
Chang WW; Lin RJ; Yu J; Chang WY; Fu CH; Lai A; Yu JC; Yu AL
Breast Cancer Res; 2013 May; 15(3):R39. PubMed ID: 23663564
[TBL] [Abstract][Full Text] [Related]
15. Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2.
Bid HK; Zhan J; Phelps DA; Kurmasheva RT; Houghton PJ
Mol Cancer Ther; 2012 Mar; 11(3):649-59. PubMed ID: 22188815
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
Beltran PJ; Chung YA; Moody G; Mitchell P; Cajulis E; Vonderfecht S; Kendall R; Radinsky R; Calzone FJ
J Pharmacol Exp Ther; 2011 Jun; 337(3):644-54. PubMed ID: 21385891
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
Yeh J; Litz J; Hauck P; Ludwig DL; Krystal GW
Lung Cancer; 2008 May; 60(2):166-74. PubMed ID: 18006183
[TBL] [Abstract][Full Text] [Related]
18. IGF-1R inhibition induces MEK phosphorylation to promote survival in colon carcinomas.
Wang Q; Zhang Y; Zhu J; Zheng H; Chen S; Chen L; Yang HS
Signal Transduct Target Ther; 2020 Aug; 5(1):153. PubMed ID: 32843616
[TBL] [Abstract][Full Text] [Related]
19. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells.
Bertrand FE; Steelman LS; Chappell WH; Abrams SL; Shelton JG; White ER; Ludwig DL; McCubrey JA
Leukemia; 2006 Jul; 20(7):1254-60. PubMed ID: 16642049
[TBL] [Abstract][Full Text] [Related]
20. IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma.
Wan X; Yeung C; Heske C; Mendoza A; Helman LJ
Neoplasia; 2015 Apr; 17(4):358-66. PubMed ID: 25925378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
